TOPICAL DRUG DELIVERY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On January 22, 2024, Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical firm, announced the launch of ZORYVE (roflumilast) topical foam, 0.3%, in the U.S. for the treatment of seborrheic dermatitis in people aged nine and ZORYVE is a once-daily steroid-free foam that is the first medicine approved for seborrheic dermatitis with a new mechanism of action in over two decades.
• In November 2023, NFlection Therapeutics Inc., a company developing topical MEK inhibitors for RAS-mediated skin conditions, announced positive topline results from a randomized, double-blind, vehicle-controlled Phase 2b clinical trial (NCT05005845). The trial evaluated NFX-179 Gel as a treatment for cutaneous neurofibromas (cNFs) in people with neurofibromatosis type 1 (NF1), a rare genetic condition.
• In June 2023, Novaliq GmbH, a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE (cyclosporine ophthalmic solution) 0.1% for the treatment of dry eye symptoms. VEVYE (development name CyclASol) is the first and only cyclosporine solution approved to treat the signs and symptoms of dry eye disease, with efficacy demonstrated within 4 weeks of treatment.
• In April 2022, Nobelpharma America, LLC, a pharmaceutical and medical device company, stated that the U.S. FDA has approved HYFTOR (sirolimus topical gel) 0.2% as the first topical treatment indicated for facial angiofibroma associated with TSC in adults and children aged six and above. HYFTOR is classified as an orphan drug for this indication.